Efficacy and Safety Evaluation After Conversion From Twice-Daily to Once-Daily Tacrolimus in Stable Liver Transplant Recipients: A Phase 4, Open-Label, Single-Center Study.
Kang WH, Song GW, Moon DB, Hwang S, Kim KH, Jung DH, Park GC, Yoon YI, Cho HD, Kim M, Kim SH, Na BG, Kim SM, Yang G, Lee SG.
Kang WH, et al.
Transplant Proc. 2021 Dec;53(10):3000-3006. doi: 10.1016/j.transproceed.2021.09.043. Epub 2021 Nov 11.
Transplant Proc. 2021.
PMID: 34776265
Clinical Trial.
There were 37 adverse reactions after conversion; most of them were mild, and thrombocytopenia developed in 1 patient as an adverse drug response. Drug compliance improved after conversion according to questionnaire responses. ...
There were 37 adverse reactions after conversion; most of them were mild, and thrombocytopenia developed in 1 patient as an adverse …